LIR Life Sciences Corp.
SKNY
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | -561.62% | -1,840.75% | -359.93% | -207.23% | |
| Total Depreciation and Amortization | -- | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -- | -- | -- | -- | |
| Change in Net Operating Assets | -124.97% | -778.89% | 469.65% | 285.96% | |
| Cash from Operations | -434.27% | -3,013.44% | 94.08% | -119.38% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -44.00% | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -100.00% | -100.00% | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 57.50% | -- | -- | -- | |
| Cash from Financing | 98.17% | -100.00% | -- | -44.08% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -22.43% | -161.70% | 1,237.43% | -390.88% | |